Genfit (GNFT) announced that Ipsen’s Iqirvo has been granted pricing and reimbursement in Italy for Primary Biliary Cholangitis. This step unlocks a new milestone payment of EUR 26.5M under its licensing and collaboration agreement with Ipsen (IPSEY), due upon pricing and reimbursement of Iqirvo in three European markets.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNFT:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue